DiaGenic ASA Provides Update on Key Clinical Programs

Published: Jul 29, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) announces that the validation study for MCItect®, a blood based diagnostic test for Alzheimer’s disease in the pre-dementia stage, has failed to reach the study goals. Consequently, DiaGenic will not pursue CE-marking or U.S. trials with the current version of MCItect®. The clinical study for the company’s other key product AMYtect™ has successfully recruited 100 patients and will enter the analysis phase in August. In the development of MCItect®, DiaGenic reported results on July 17th 2012 from a 60-patient study demonstrating a total prediction accuracy of 74% in detecting patients converting from mild cognitive impairment to Alzheimer’s disease dementia. Utilizing an improved assay methodology and instrumentation, a separate non-overlapping subset of genes increased the prediction accuracy to 81%.

Help employers find you! Check out all the jobs and post your resume.

Back to news